Mary Kay Fenton - 18 Feb 2026 Form 4 Insider Report for Cullinan Therapeutics, Inc. (CGEM)

Role
Chief Financial Officer
Signature
/s/ Jacquelyn Sumer, Attorney-in-Fact
Issuer symbol
CGEM
Transactions as of
18 Feb 2026
Net transactions value
$0
Form type
4
Filing time
19 Feb 2026, 17:00:05 UTC
Previous filing
05 Jan 2026
Next filing
23 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Fenton Mary Kay Chief Financial Officer C/O CULLINAN THERAPEUTICS, INC., ONE MAIN STREET, SUITE 1350, CAMBRIDGE /s/ Jacquelyn Sumer, Attorney-in-Fact 19 Feb 2026 0001378589

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CGEM Common Stock Award $0 +68,750 +111% $0.000000 130,778 18 Feb 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CGEM Stock Option (Right to Buy) Award $0 +137,500 $0.000000 137,500 18 Feb 2026 Common Stock 137,500 $12.44 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the restricted stock unit vest on an annual basis over four years.
F2 The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.